PDF(Pubmed)
Abstract：
UNASSIGNED: Cirrhosis of liver is associated with loss of liver function, portal hypertension, and pancreatic β-cell dysfunction leading to hepatogenous diabetes (HD). Often HD is an underestimated and understudied problem, particularly in the Indian subcontinent, where the prevalence of both Chronic liver disease (CLD) and diabetes is high. Hence this study was planned to highlight the prevalence of HD and its association with the severity of cirrhosis.
UNASSIGNED: A total of 121 cirrhotic patients without a history of diabetes were included in this prospective cross-sectional study. Seventy five g oral glucose tolerance test (OGTT) was done in all patients. Fasting serum insulin levels were done to calculate insulin resistance (IR) using homeostatic model assessment-insulin resistance (HOMA-IR). Upper gastrointestinal endoscopy was done to detect varices. Patients were divided into HD group and non-HD group for comparison of results.
UNASSIGNED: HD was seen in 52 (42.98%) patients; among them, 63.4% did not show evidence of HD by fasting plasma glucose (FPG) levels. Impaired glucose tolerance (IGT) was seen in 58 (47.93%) patients. Compared with the non-HD group, the HD group had significantly higher model for end-stage liver disease (MELD) score (P = 0.038), HOMA-IR (P < 0.001), incidence of large varices (P < 0.001) and variceal bleeding (P < 0.001). A statistically significant association was noted between HD and Hepatocellular carcinoma (HCC) (P < 0.001).
UNASSIGNED: Patients with cirrhosis had a high prevalence of IGT, IR, and HD. The presence of HD is well associated with the severity of cirrhosis in the form of higher MELD score (>15), CTP score (>10), higher bilirubin levels, large varices, bleeding varices, and HCC. FPG levels and glycated hemoglobin (HbA1c) cannot be relied upon, and OGTT aids in the unmasking of HD in these patients.
UNASSIGNED: A total of 121 cirrhotic patients without a history of diabetes were included in this prospective cross-sectional study. Seventy five g oral glucose tolerance test (OGTT) was done in all patients. Fasting serum insulin levels were done to calculate insulin resistance (IR) using homeostatic model assessment-insulin resistance (HOMA-IR). Upper gastrointestinal endoscopy was done to detect varices. Patients were divided into HD group and non-HD group for comparison of results.
UNASSIGNED: HD was seen in 52 (42.98%) patients; among them, 63.4% did not show evidence of HD by fasting plasma glucose (FPG) levels. Impaired glucose tolerance (IGT) was seen in 58 (47.93%) patients. Compared with the non-HD group, the HD group had significantly higher model for end-stage liver disease (MELD) score (P = 0.038), HOMA-IR (P < 0.001), incidence of large varices (P < 0.001) and variceal bleeding (P < 0.001). A statistically significant association was noted between HD and Hepatocellular carcinoma (HCC) (P < 0.001).
UNASSIGNED: Patients with cirrhosis had a high prevalence of IGT, IR, and HD. The presence of HD is well associated with the severity of cirrhosis in the form of higher MELD score (>15), CTP score (>10), higher bilirubin levels, large varices, bleeding varices, and HCC. FPG levels and glycated hemoglobin (HbA1c) cannot be relied upon, and OGTT aids in the unmasking of HD in these patients.
摘要：
未经证实：肝硬化与肝功能丧失有关，门静脉高压症,和胰腺β细胞功能障碍导致肝源性糖尿病（HD）。通常，HD是一个被低估和研究不足的问题，尤其是在印度次大陆，慢性肝病（CLD）和糖尿病的患病率很高。因此，这项研究计划强调HD的患病率及其与肝硬化严重程度的关系。
UNASSIGNED：这项前瞻性横断面研究共纳入了121例无糖尿病史的肝硬化患者。所有患者均进行75g口服葡萄糖耐量试验（OGTT）。使用稳态模型评估-胰岛素抵抗（HOMA-IR）进行空腹血清胰岛素水平以计算胰岛素抵抗（IR）。进行上消化道内镜检查以检测静脉曲张。将患者分为HD组和非HD组进行结果比较。
未经证实：52例（42.98％）患者出现HD；其中，63.4％的空腹血糖（FPG）水平未显示出HD的证据。58例（47.93％）患者出现葡萄糖耐量（IGT）受损。与非HD组相比,HD组有明显更高的终末期肝病模型（MELD）评分（P=0.038），HOMA-IR（P<0.001），大静脉曲张（P<0.001）和静脉曲张出血（P<0.001）的发生率。HD与肝细胞癌（HCC）之间存在统计学上的显着关联（P<0.001）。
未经证实：肝硬化患者IGT患病率高，IR,和HD。HD的存在与较高MELD评分（>15）的肝硬化严重程度密切相关，CTP评分(>10),更高的胆红素水平，大静脉曲张,静脉曲张出血,和HCC。FPG水平和糖化血红蛋白（HbA1c）不能依赖，和OGTT有助于揭开这些患者的HD。
UNASSIGNED：这项前瞻性横断面研究共纳入了121例无糖尿病史的肝硬化患者。
未经证实：52例（42.98％）患者出现HD；其中，
未经证实：肝硬化患者IGT患病率高，
